Analysts at B. Riley issued their Q1 2025 EPS estimates for LifeMD in a research report issued to clients and investors on Tuesday, March 11th. B. Riley analyst A. Schock anticipates that the company ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Good afternoon. Thank you for joining us to discuss LifeMD, Inc.

LifeMD Inc (LFMD) reports a 43% revenue increase and unveils plans for new product launches and Medicare offerings amid ...

Thank you for joining us to discuss LifeMD Inc fourth-quarter and full-year 2024 earnings results. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, ...

H.C. Wainwright analyst Yi Chen raised the firm’s price target on LifeMD (LFMD) to $14 from $12 and keeps a Buy rating on the shares. The ...

Q4 2024 Results Conference Call March 10, 2025 4:30 PM ETCompany ParticipantsJustin Schreiber - Chairman and Chief ...

In a report released on March 11, Steven Valiquette from Mizuho Securities maintained a Hold rating on LifeMD (LFMD – Research Report). The ...

LifeMD reported a fourth-quarter loss per share of 2 cents. Analysts were expecting a loss of 5 cents per share, according to FactSet. Revenue for the fourth quarter came in at $64.3 million. Analysts ...

LifeMD has a 12 month low of $3.99 and a 12 month high of $12.88. The company has a market capitalization of $241.25 million, a P/E ratio of -8.70 and a beta of 1.50.

Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60%Adjusted EBITDA increased 78% to $9.0 millionTelehealth adjusted EBITDA increased 396% to $5.9 million ...

LifeMD Inc (LFMD) reported a robust financial performance for the fourth quarter of 2024, significantly surpassing market expectations with an earnings per share (EPS) of $0.21 against a ...